Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?
60% Reduction In Tau Exceeds Expectations
Executive Summary
Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.
You may also be interested in...
First Signs Of Efficacy From Biogen’s Tau-Targeting Antisense Drug
After showing an impressive 60% reduction in tau levels in the brain, Biogen’s Phase I study of BIIB080 has now demonstrated early signs of an impact on cognition and daily living for Alzheimer’s patients.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.
Alnylam Buoyed By Early Alzheimer’s Gene Silencing Success
Alnylam has unveiled Phase I data showing its RNAi candidate can eliminate the amyloid precursor protein in the brain – opening the door to treating Alzheimer’s and many more CNS diseases.